JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on December 13, 2002; DOI: 10.1124/jpet.102.045856


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.102.045856v1
304/3/1268    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allen, D. D.
Right arrow Articles by Crooks, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allen, D. D.
Right arrow Articles by Crooks, P. A.

Vol. 304, Issue 3, 1268-1274, March 2003

Active Transport of High-Affinity Choline and Nicotine Analogs into the Central Nervous System by the Blood-Brain Barrier Choline Transporter

David D. Allen, Paul R. Lockman, Karen E. Roder, Linda P. Dwoskin and Peter A. Crooks

Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University HSC, Amarillo, Texas (D.D.A., P.R.L., K.E.R.); and Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky (L.P.D., P.A.C.)

Cigarette smoking is strongly implicated in the development of cardiovascular disorders. Recently identified nicotinium analogs may have therapeutic benefit as smoking cessation therapies but may have restricted entry into the central nervous system by the blood-brain barrier (BBB) due to their physicochemical properties. Using the in situ perfusion technique, lobeline, choline, and nicotinium analogs were evaluated for binding to the BBB choline transporter. Calculated apparent Ki values for the choline transporter were 1.7 µM N-n-octyl choline, 2.2 µM N-n-hexyl choline, 27 µM N-n-decylnicotinium iodide, 31.9 µM N-n-octylpyridinium iodide, 49 µM N-n-octylnicotinium iodide (NONI), 393 µM lobeline, and >= 1000 µM N-methylnicotinium iodide. Nicotine and N-methylpyridinium iodide, however, do not apparently interact with the BBB choline transporter. Given NONI's apparent Ki value determined in this study and its ability to inhibit nicotine-evoked dopamine release from superfused rat brain slices, potential brain entry of NONI via the BBB choline transporter was evaluated. [3H]NONI exhibited a BBB transfer coefficient value of ~1.6 × 10-3 ml/s/g and a Km of ~250 µM. Unlabeled choline addition to the perfusion fluid reduced [3H]NONI brain uptake. We hypothesize the N-n-octyl group on the pyridinium nitrogen of NONI facilitates brain entry via the BBB choline transporter. Thus, NONI may have utility as a smoking cessation agent, given its ability to inhibit nAChRs mediating nicotine-evoked dopamine release centrally, and to be distributed to brain via the BBB choline transporter.


0022-3565/03/3043-1268$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
MicrobiologyHome page
P. Ganas and R. Brandsch
Uptake of L-nicotine and of 6-hydroxy-L-nicotine by Arthrobacter nicotinovorans and by Escherichia coli is mediated by facilitated diffusion and not by passive diffusion or active transport
Microbiology, June 1, 2009; 155(6): 1866 - 1877.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
Z. A. F. Albayati, L. P. Dwoskin, and P. A. Crooks
Pharmacokinetics of the Novel Nicotinic Receptor Antagonist N,N'-Dodecane-1,12-diyl-bis-3-picolinium Dibromide in the Rat
Drug Metab. Dispos., October 1, 2008; 36(10): 2024 - 2029.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. P. Dwoskin, T. E. Wooters, S. P. Sumithran, K. B. Siripurapu, B. M. Joyce, P. R. Lockman, V. K. Manda, J. T. Ayers, Z. Zhang, A. G. Deaciuc, et al.
N,N'-Alkane-diyl-bis-3-picoliniums as Nicotinic Receptor Antagonists: Inhibition of Nicotine-Evoked Dopamine Release and Hyperactivity
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 563 - 576.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. R. Lockman, V. K. Manda, W. J. Geldenhuys, R. K. Mittapalli, F. Thomas, Z. F. Albayati, P. A. Crooks, L. P. Dwoskin, and D. D. Allen
Carrier-Mediated Transport of the Quaternary Ammonium Neuronal Nicotinic Receptor Antagonist N,N'-Dodecylbispicolinium Dibromide at the Blood-Brain Barrier
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 244 - 250.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.